Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 61-71

  Jamois, Candice ^a,b   Comets, Emmanuelle ^c   Mentré, France ^c   Marion, Sylvie ^d   Farinotti, Robert ^b,e   Bonhomme Faivre, Laurence ^a,b  

^a Service Pharmacie   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d Service d'Hématologie   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Neutrophil toxicity; Oral administration; Paclitaxel; Pharmacokinetic; Recombinant interleukin 2

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; HEMATOLOGICAL PARAMETERS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; INTERLEUKIN-2; MICE; NEUTROPHILS; PACLITAXEL;

EID: 11244251943     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0824-z     Document Type: Article

References (47)

1. Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SD, Gilissen R, van Houdt J, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579
2. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303
3. Bonhomme-Faivre L, Pelloquin A, Tardivel S, Mathieu MC, Castagne V, Lacour B, Farinotti R (2002) Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer Drugs 13:1
4. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevalier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187
5. Burtin P, Mentré F, van Bree J, Steimer JL (1996) Sparse sampling for assessment of drug exposure in toxicological studies. Eur J Drug Metab Pharmacokinet 21(2):105
6. Cantoni L, Carelli A, Ghezzi P, Delgado R, Faggioni R, Rizzardini M (1995) Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. Eur J Pharmacol 292:257
7. Castagne V, Bonhomme Faivre L, Urien S, Reguiga MB, Soursac M, Gimenez F, Farinotti R (2004) Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and p-glycoprotein activity in mice. Drug Metab Dispos 32(2):168
8. Comets E, Mentré F, Kawai R, Nimerfall F, Marbach P, Vonderscher J (2000) Modelling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. J Pharm Sci 89:1123
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597
10. Demario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557
11. Eiseman JL, Eddington ND, Leslie J, Mc Auley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorim MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465
12. Friberg LE, Freijs A, Sandström M, Karlsson MO (2000) Semiphysiological model for the time course of leucocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734
13. Hing JP, Woolfrey SG, Greenslade D, Wright PM (2001) Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 28:465
14. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473
15. Huet S, Bouvier A, Gruet MA, Jolivet E (1996) Statistical tools for nonlinear regression: a practical guide with S-Plus examples. Springer, New York
16. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Invest 13:381
17. Ihaka R, Gentleman R (1996) A language for data analysis and graphics. J Comput Graph Statist 5(3):299
18. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R (1998) A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63:11
19. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, Mc Donald E, Kukulku MJ, Hsu A, Granneman GR, Baroldi PA, et al (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654
20. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110
21. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histological findings. JAMA 256:3117
22. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319
23. Malingre MM, Beijnen JH, Schellens JHM (2001) Oral delivery of taxanes. Invest New Drugs 19:155
24. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH (2001) Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1):42
25. Meerum Terwogt JM, Schellens JHM, ten Bokkel Huinink WW, Beijnen JH (1999) Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 25:83
26. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485
27. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston Lirehan W, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2-alone. N Engl J Med 316:889
28. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004
29. Salphati L, Benet LZ (1998) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308
30. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, Te Riele HPJ, et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491
31. Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A co-ordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311
32. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Non linear murine pharmacokinetics of paclitaxel results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112
33. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031
34. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454
35. Stein U, Wather W, Shoemaker RH (1996) Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 74:1384
36. Terao T, Hisagana E, Sai Y, Tamai I, Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083
37. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willigham MC (1987) Cellular localization of the multi-drug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735
38. Van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181
39. Van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 4:2293
40. van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125
41. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, Lacour B, Farinotti R (2002) Effect of Interleukin-2 on Intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 302:742
42. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW (2001) No influence of the MDR-1 C3435 T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentration or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048
43. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129
44. Wacher VJ, Salphati L, Benet LZ (1996) Active secretion and enterocystic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 20:99
45. West WH, Tauer KW, Vannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898
46. Willey TA, Bekos EJ, Gaver R, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621:231
47. Woodcock DM, Jefferson S, Linsenmeijer ME, et al (1990) Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199